Stockscreener 앱 받기
188.42
2.74%
5.02
시간 외 거래:
189.05
0.63
+0.33%
전일 마감가:
$183.40
열려 있는:
$190.88
하루 거래량:
2.76M
Relative Volume:
0.63
시가총액:
$292.21B
수익:
$58.80B
순이익/손실:
$10.24B
주가수익비율:
57.47
EPS:
3.2788
순현금흐름:
$8.98B
1주 성능:
+2.63%
1개월 성능:
-9.61%
6개월 성능:
+155.45%
1년 성능:
+158.68%
1일 변동 폭
$187.95
$192.97
1주일 범위
$182.39
$192.97
52주 변동 폭
$61.24
$212.71
아스트라제네카 ADR Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
188.42 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
LLY
Lilly Eli Co
|
878.24 | 784.58B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.45 | 579.15B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
209.40 | 370.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.63 | 295.77B | 64.93B | 18.26B | 12.36B | 7.2751 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 개시 | Citigroup | Buy |
| 2025-10-27 | 재개 | Jefferies | Buy |
| 2025-10-16 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
Can AstraZeneca Shape FTSE 100 Momentum? - Kalkine Media
USA Financial Formulas Acquires Shares of 10,063 Astrazeneca Plc $AZN - MarketBeat
Chesley Taft & Associates LLC Acquires 25,985 Shares of Astrazeneca Plc $AZN - MarketBeat
AstraZeneca Stock Climbs After Experimental COPD Drug Meets Late-Stage Trial Goals - TIKR.com
iShares World ex U.S. Carbon Transition Readiness Aware Active ETF's AstraZeneca PLC(LSE:AZN) Holding History - GuruFocus
How Astrazeneca Plc (AZN) Affects Rotational Strategy Timing - Stock Traders Daily
Nordea Investment Management AB Grows Holdings in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca (NYSE:AZN) Gains Sharply Amid Rising Healthcare Market Strength - Kalkine Media
Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors - Yahoo Finance
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results - The Chronicle-Journal
ETFs Investing in AstraZeneca PLC Stocks - TradingView
AstraZeneca advances Friday, outperforms market - MarketWatch
UK's FTSE 100 Ends Week Little Changed; AstraZeneca Shares Gain - marketscreener.com
AstraZeneca Expands DNA-Repair Oncology Pipeline With New AZD4956 Combination Trial - TipRanks
Astrazeneca (NYSE:AZN) Shares Gap UpHere's What Happened - MarketBeat
AstraZeneca lung drug gets ‘surprise’ win in COPD trials - BioPharma Dive
FTSE 100 movers: AstraZeneca jumps on COPD drug news; Metlen slumps - London South East
Buying pressure lifts AstraZeneca stock higher in today's trading - Traders Union
ASTRAZENECA : Receives a Buy rating from Barclays - marketscreener.com
ASTRAZENECA : Jefferies maintains a Buy rating - marketscreener.com
ASTRAZENECA : JP Morgan remains its Buy rating - marketscreener.com
International ETFs: EEM and IEFA Offer Distinct Global ETF Choices - The Motley Fool
AstraZeneca drug reduces flare-ups of chronic lung disease in late-stage trials - London South East
Concerning safety signals and positive efficacy for AstraZeneca’s in vivo CAR-T - Clinical Trials Arena
AstraZeneca Maintained at Buy as BofA Notes Positive Tozorakimab Late-stage Data - marketscreener.com
AstraZeneca (AZN.US) Experimental Lung Disease Drug Meets Targets in Late-Stage Trials; Stock Rises 4% Pre-Market - AASTOCKS.com
Why Is AstraZeneca Stock Gaining Friday?AstraZeneca (NYSE:AZN) - Benzinga
AstraZeneca’s novel COPD drug secures double win in Phase III - Clinical Trials Arena
AstraZeneca PLC Announces Tozorakimab Meets Primary Endpoints in OBERON and TITANIA Phase III Trials - marketscreener.com
AstraZeneca (AZN) reports Phase III COPD success for IL‑33 biologic tozorakimab - Stock Titan
AstraZeneca posts Phase 3 trial win for COPD drug (AZN:NYSE) - Seeking Alpha
AstraZeneca Scores First IL-33 Win In COPD With Tozarakimab - insights.citeline.com
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD - AstraZeneca
FTSE 100 Live: Middle East conflict hits consumer sentiment, AstraZeneca jumps 2.9% - Analytics Insight
AstraZeneca stock gains on positive COPD trial results - Investing.com
AstraZeneca's COPD candidate succeeds in twin Phase III studies - Sharecast.com
AstraZeneca PLC: Good timing to anticipate a continuation of the trend - marketscreener.com
AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials - proactiveinvestors.com
AstraZeneca hails positive results in tozorakimab lung disease trials - London South East
AstraZeneca says tozorakimab meets primary endpoint in Oberon and Titania phase III COPD trials - marketscreener.com
AstraZeneca Achieves Breakthrough with Tozorakimab in COPD Trials - Devdiscourse
AstraZeneca drug reduces COPD flare ups in late-stage trials - Reuters
AstraZeneca : Tozorakimab met OBERON/TITANIA primary endpoints - marketscreener.com
Morgan Stanley sees double-digit EPS growth for AstraZeneca PLC (AZN) - MSN
Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma - Barchart
ASTRAZENECA : Receives a Sell rating from Deutsche Bank - marketscreener.com
AstraZeneca PLC ADRhedged (AZNH) Stock Price, Holdings, Dividend Yield - GuruFocus
Cash per share of AstraZeneca PLC – SWB:ZEG - TradingView
Astrazeneca Plc (NYSE:AZN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Sit International Growth Fund's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca plc stock faces pipeline scrutiny amid oncology setbacks and regulatory delays in key ma - AD HOC NEWS
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.59%
1.02%
자본화:
|
볼륨(24시간):